Actuate to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Actuate will present and host one-on-one investor meetings at the H.C. Wainwright Global Investment Conference, with a webcast available online.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Actuate Therapeutics (ACTU) will deliver a corporate presentation at the H.C. Wainwright 28th Annual Global Investment Conference in New York City on Monday, September 14, 2026, at 4:00 PM ET.
The company’s management will also be available for one-on-one meetings during the September 14–16, 2026 event, and a webcast of the presentation will be accessible via the Investor section of Actuate’s website.
Details
Market move: ACTU -8.73% in the Sep 10 session. conference presentation
On Sep 10, the first trading day after this news, ACTU closed 8.73% below the previous close. Argus tracked a trough of -5.9% from its starting point during tracking. Our momentum scanner recorded 7 alerts for this stock that day.
Data tracked by StockTitan Argus for the Sep 10 session.
Key Figures
- Presentation date
- September 14, 2026
- H.C. Wainwright Global Investment Conference
- Presentation time
- 4:00 PM ET
- Corporate presentation
AI-generated analysis. How Rhea-AI works. Not financial advice.
CHICAGO and FORT WORTH, Texas, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company, focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers, today announced that it will present at the H.C. Wainwright 28th Annual Global Investment Conference taking place September 14-16, 2026, in New York City. In addition, the management team will be available for one-on-one meetings during the conference.
Details on the presentation:
Format: Corporate Presentation
Date: Monday, September 14, 2026
Time: 4:00 PM ET
Webcast Link: click here
The webcast of the presentation will be accessible in the Investor section of the Actuate website
About Actuate Therapeutics, Inc.
Actuate is a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers. Actuate’s lead investigational drug, elraglusib (a novel GSK-3β inhibitor), targets molecular pathways in cancer that are involved in promoting tumor growth and resistance to conventional cancer drugs such as chemotherapy through the inhibition of nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kB) and DNA Damage Response (DDR). Elraglusib may also mediate anti-tumor immunity through the regulation of multiple immune checkpoints and immune cell function.
For additional information, please visit the Company’s website at www.actuatetherapeutics.com or follow us on LinkedIn, X, and Facebook.
Investor Contact
Mike Moyer
Managing Director
LifeSci Advisors, LLC
mmoyer@lifesciadvisors.com
Media Contact
Ignacio Guerrero-Ros, Ph.D.
Russo Partners, LLC
Ignacio.guerrero-ros@russopartnersllc.com
(858) 717-2310
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
When and where will Actuate Therapeutics present at the H.C. Wainwright conference?
The corporate presentation is scheduled for Monday, September 14, 2026, at 4:00 PM ET during the H.C. Wainwright 28th Annual Global Investment Conference in New York City.
How can investors access the Actuate Therapeutics presentation remotely?
A webcast of the presentation will be accessible in the Investor section of the Actuate Therapeutics website.
Will Actuate’s management be available for individual investor meetings at the conference?
Yes. The management team will be available for one-on-one meetings during the September 14–16, 2026 conference.